Helix and Recursion Pharmaceuticals Drive Drug Discovery Innovation Through Clinico-Genomic Data
Access to Helix’s large-scale clinico-genomic data to drive creation and training of AI models
Recursion will have access to de-identified clinico-genomic data, collected from research participants who consent to participate in Helix’s extensive research network, which includes health systems from across the US. These population-scale cohorts, consisting of full longitudinal clinical records paired with genomic data, span multiple germline therapeutic areas. Recursion plans to utilize this data to train causal AI models to accelerate drug discovery, design biomarkers, and develop patient stratification strategies across a range of disease states.
“Recursion’s AI-enabled drug discovery strategy relies on access to diverse multimodal datasets. By combining the Helix clinico-genomic dataset with over [25] petabytes of Recursion’s proprietary biological and chemical data, we hope to unlock new insights that will allow us to increase the speed, efficacy, and scale in the development of precision medicines across a wide range of diseases,” said
“This partnership with
About Helix
Helix is the leading population genomics company, enabling health systems, life sciences organizations and payers to accelerate the integration of genomic data into patient care and therapeutic development. Learn more at https://www.helix.com/life-sciences.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240624651491/en/
helix@consortpartners.com
Source: Helix